Pharmaceuticals business rationalization, U.S. growth strategy and pipeline expansion
First written in FY2024. 2 of 4 entries say "Advanced", first in FY2025-H1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026ReframedAnnual report
「Accordingly, in the current consolidated fiscal year, the businesses of the company and its subsidiaries and other entities were classified as discontinued operations, while the previous consolidated fiscal year was also restated and the discontinued operations presented separately.」
The themes of pharmaceuticals business rationalization, U.S. growth and pipeline expansion changed from continuing operations to discontinued operations following the transfer of 田辺三菱製薬. - FY2025AdvancedAnnual report
「The Company had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding ND0612. After discussing with the FDA the provision of additional information on the safety of carbidopa, one of ND0612’s components identified in the CRL, as well as additional information concerning product quality, the device and inspections of manufacturing facilities, the Company changed its development plan in the United States after confirming the steps required for resubmission. It aims to resubmit the application in mid-2025. In February 2025, it also received notification from the European Medicines Agency (EMA) that its marketing authorization application had been accepted.」
Regarding pharmaceuticals pipeline expansion, the Company progressed to changing the development plan for ND0612 in preparation for resubmission in the United States, targeting mid-2025, and to acceptance of the marketing authorization application in Europe. - FY2025-H1AdvancedAnnual report
「In March 2024, the Company received from the U.S. Food and Drug Administration seven-year orphan drug exclusivity for the use of the U.S. product “RADICAVA ORS®” (generic name: edaravone) to treat ALS (amyotrophic lateral sclerosis), beginning with the approval of “RADICAVA ORS®” on 12 May 2022. In July 2024, 田辺三菱製薬株式会社 announced the implementation of a voluntary early-retirement program to accelerate the review of its talent portfolio, with the aim of placing personnel with the capabilities required to execute its growth strategy and creating an organization in which highly specialized and diverse talent can thrive, as it seeks to become a company that grows in global markets.」
Regarding the pharmaceuticals business’s U.S. growth strategy, the Company obtained seven-year orphan drug exclusivity for RADICAVA ORS. It also announced a review of its talent portfolio and a voluntary early-retirement program for future business growth and rationalization. - FY2024First statedAnnual report
「- Rationalization of the pharmaceuticals business and pipeline expansion: consideration and implementation of measures for the U.S. growth strategy and in preparation for the end of the exclusive marketing period for the amyotrophic lateral sclerosis (ALS) treatment RADICAVA, which has been extended through FY2029」
For the pharmaceuticals business, the Company first explicitly identified the U.S. growth strategy, pipeline expansion and business rationalization as issues to address with FY2029 in view, when the exclusive marketing period for RADICAVA is expected to end.